MORPHINE SULFATE INJECTION, USP SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

MORPHINE SULFATE

Saatavilla:

FRESENIUS KABI CANADA LTD

ATC-koodi:

N02AA01

INN (Kansainvälinen yleisnimi):

MORPHINE

Annos:

8MG

Lääkemuoto:

SOLUTION

Koostumus:

MORPHINE SULFATE 8MG

Antoreitti:

INTRAMUSCULAR

Kpl paketissa:

1ML

Prescription tyyppi:

Narcotic (CDSA I)

Terapeuttinen alue:

OPIATE AGONISTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0104545020; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2018-11-13

Valmisteyhteenveto

N
_Morphine Sulfate Injection, USP _
_ _
_ _
Page 1 of 30
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION, USP
Sterile Solution
2 mg / mL, 4 mg / mL, 5 mg / mL, 8 mg / mL and 10 mg / mL
Intravenous, Intramuscular, and Subcutaneous
Narcotic Analgesic
Date of Preparation: November 13, 2018
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100,
Toronto, ON, M9W 0C8
Control No: 213924
Morphine Sulfate Injection, USP-Product Monograph
Page
2
of
30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
3
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
12
DRUG INTERACTIONS
.........................................................................................................................
14
DOSAGE AND ADMINISTRATION
...................................................................................................
15
OVERDOSAGE
.........................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
................................................................................
20
STORAGE AND STABILITY
................................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
.........................................................